Christopher E. Nelson

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Assistant Professor

University of Arkansas primary UA Little Rock Arkansas State University

Also affiliated: Dartmouth College (1994–1995); University of North Carolina at Chapel Hill (2024); Oak Ridge National Laboratory (2025); United States Department of Agriculture (1953); North Carolina State University (2024); Lawrence Berkeley National Laboratory (2002–2015); Cooperative Institute for Research in Environmental Sciences (1998); Duke University (2014–2021); Iowa State University (1991); University of Colorado Boulder (1998–2004); Vanderbilt University (2011–2016); University of Colorado System (2001); UnityPoint Health (1991); Kemin (Belgium) (1991–1993); Duke Medical Center (2015–2017); Dow Chemical (United States) (1951–2023); KLA (Israel) (2007); KLA (Ireland) (2007); Molecular Foundry (2015); Iowa Department of Transportation (1991); KLA (United States) (1999–2007); Washington State University (1967–1983); Iowa Department of Natural Resources (1991); Morehouse College (1989); Michigan State University (2002); Atlanta University Center (1989)

38 h-index 142 pubs 5,951 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group

OverviewAI-generated summary

Christopher E. Nelson's research focuses on gene editing technologies, particularly CRISPR-Cas systems, and their application in treating genetic disorders. His work has investigated in vivo genome editing to improve muscle function in mouse models of Duchenne muscular dystrophy and has evaluated the long-term efficacy of AAV-CRISPR gene editing for this condition. Nelson has also explored immune responses to Cas9, which can affect the efficacy of CRISPR-based therapies in canine models of muscular dystrophy. His research extends to developing non-viral delivery methods for CRISPR/Cas9, aiming for targeted gene replacement.

Beyond gene editing, Nelson's work includes the development of drug delivery systems. He has studied ROS-responsive microspheres for antioxidant therapy in diabetic peripheral arterial disease and poly(PS-b-DMA) micelles for reactive oxygen species-triggered drug release. Additionally, he has investigated methods for evaluating endosomolytic agents for the cytosolic delivery of biomacromolecular drugs, such as an ex vivo red blood cell hemolysis assay. Nelson has secured federal funding from the NIH and NSF for his research, totaling over $1 million, to explore gene therapy durability and non-viral delivery systems. His scholarship metrics include an h-index of 38, 145 publications, and over 5,900 citations.

Metrics

h-index: 38
Publications: 142
Citations: 5,951

Positions

Assistant Professor 2019–present

University of Arkansas Department of Biomedical Engineering ORCID

Selected Publications

CRISPR-Cas9-Mediated Knock-In of Salmo salar elovl2 Enhances Endogenous Omega-3 Fatty Acid Biosynthesis in Zebrafish (Danio rerio) (2026)

SSRN Electronic Journal DOI OpenAlex
CRISPR-Cas9 mediated gene insertion of Salmo salar Elovl2 in zebrafish (Danio rerio) at early stage of embryonic development (2026)

Gene Reports 1 citation DOI OpenAlex
Targeting mitochondrial dynamics via OPA1 overexpression and BNIP3 knockdown confers protection against pancreatic cancer induced muscle dysfunction (2026)

Physiology DOI OpenAlex
OPTIMIZATION OF PRODUCTION, QUANTIFICATION, AND QUALIFICATION OF LENTIVIRAL VECTORS (2026)

Cytotherapy DOI OpenAlex
Beyond the Cut: Long-read sequencing reveals complex genomic and transcriptomic changes in AAV-CRISPR therapy for Duchenne Muscular Dystrophy (2025)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
Standardizing a Protocol for Streamlined Synthesis and Characterization of Lipid Nanoparticles to Enable Preclinical Research and Education (2025)

bioRxiv (Cold Spring Harbor Laboratory) 1 citation DOI OpenAlex
A dual-fluorescence assay for gene delivery vehicle screening in macrophages with an inflammation-inducible reporter construct (2025)

BMC Methods DOI OpenAlex
Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping (2025)

Journal of Neuromuscular Diseases 2 citations DOI OpenAlex
Resistance to Acetyl Coenzyme A Carboxylase (ACCase) Inhibitor in Lolium multiflorum: Effect of Multiple Target-Site Mutations (2024)

Agronomy 3 citations DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

Molecular Therapy — Nucleic Acids 2 citations DOI OpenAlex
Optimizing Recombinant Cas9 Expression: Insights from E. coli BL21(DE3) Strains for Enhanced Protein Purification and Genome Editing (2024)

Biomedicines 9 citations DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

bioRxiv (Cold Spring Harbor Laboratory) 3 citations DOI OpenAlex
PINE-TREE enables efficient enrichment of prime-edited hPSCs (2023)

Molecular Therapy — Nucleic Acids DOI OpenAlex
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy (2023)

Biophysics Reviews 14 citations DOI OpenAlex
Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies (2022)

Neoplasia 6 citations DOI OpenAlex